Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest Adaptive Biotechnologies Corporation Stories

2014-04-07 12:33:36

Investment fuels expansion of industry-leading immunosequencing research platform and diagnostic products for the treatment of cancer, autoimmune disorders, and infectious diseases SEATTLE, April 7, 2014 /PRNewswire/ -- Adaptive Biotechnologies announced today the completion of the Company's Series C financing round and the completion of a newly created Series D round with a $105 million investment from Viking Global Investors. This investment will enable the Company to expand...

2014-01-13 12:27:53

SEATTLE, Jan. 13, 2014 /PRNewswire/ -- Adaptive Biotechnologies announced today a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQ(TM), to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The...

2014-01-08 12:29:43

SEATTLE, Jan. 8, 2014 /PRNewswire/ -- Adaptive Biotechnologies (www.adaptivebiotech.com) announced today that Chad Robins, Founder and Chief Executive Officer, is scheduled to present a company overview at the 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15(th), 2014 at 2:00pm PST. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) About AdaptiveAdaptive Biotechnologies Corporation ("Adaptive" or the "Company") is a pioneer in...

2013-12-03 12:27:24

Data Validates Survival Benefit of Minimal Residual Disease by clonoSEQ(TM) in Patients with T and B Cell Malignancies SEATTLE, Dec. 3, 2013 /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing (NGS) of the adaptive immune system, and its collaborators will present data demonstrating how immunosequencing can inform survival in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 7-10, 2013. (Logo:...

2013-10-25 16:24:09

Company develops Synthetic Immune System (SIS(TM)) to control for possible bias inherent in high-throughput immune sequencing; aims to develop kit for widespread distribution SEATTLE, Oct. 25, 2013 /PRNewswire/ -- Adaptive Biotechnologies Corporation, a leading provider of next-generation oncology diagnostics, announced today the publication of a method to significantly improve the accuracy of next-generation immune system profiling by creating a fully validated Synthetic Immune...

2013-10-17 12:30:16

The allowed claims cover compositions and methods that allow for Next Generation Sequencing (NGS) to be applied to cells of the adaptive immune system SEATTLE, Oct. 17, 2013 /PRNewswire/ -- Adaptive Biotechnologies Corporation, a pioneer in the field of genomic immune profiling, announced today that the Company has obtained a Notice of Allowance in U.S. Patent Application Serial No. 12/794,507, titled "Method of Measuring Adaptive Immunity," exclusively licensed by Adaptive...

2013-10-08 12:27:48

Study co-led by Fred Hutchinson Cancer Research Center dispels notion of immune system as spatially heterogeneous as cancer genome SEATTLE, Oct. 8, 2013 /PRNewswire/ -- Adaptive Biotechnologies Corporation, a leading provider of next-generation oncology diagnostics, today announced results from an ovarian cancer study, conducted in collaboration with Fred Hutchinson Cancer Research Center, highlighting the even distribution of immune fighter cells (T-cells) within the tumor. The...

2013-09-13 12:26:09

Award is for a multi-center collaboration with MD Anderson, the Fred Hutchinson Cancer Research Center, City of Hope, Duke University, and the University of Colorado SEATTLE, Sept. 13, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it received a $2.53 million Phase II Small Business Innovation Research award from the National Heart, Lung, and Blood Institute, a division of the NIH, to commercialize a test to measure the ability of a cancer patient's adaptive...

2013-06-27 12:27:52

SEATTLE, June 27, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has signed an agreement with Biogen Idec for the study of the immune repertoire and the search for immunological biomarkers in difficult to treat autoimmune diseases. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) Under the collaboration, Adaptive's proprietary immune profiling assay, immunoSEQ, will be used to characterize the immune repertoire of patient samples with...

2013-05-09 12:28:43

SEATTLE, May 9, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response. The immunoSEQ assay uses high throughput...